Monday, October 5, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· January 26, 2026

Shell Canada Joins Scene+ Loyalty Program

View original at finance.yahoo.com
Shell Canada Joins Scene+ Loyalty Program Together with Scotiabank and Tangerine, Shell Introduces New Ways to Save and Earn with Scene+ CALGARY, AB, Jan…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Through partnerships with Scene+, Scotiabank and Tangerine, customers will soon be able to earn and redeem rewards on fuel, car washes and eligible convenience store purchases at more than 1,400 Shell locations nationwide

    80% confidence

  • Scotiabank clients can make everyday spending more rewarding with their Scotiabank card, unlocking new ways to earn faster, save instantly and reward themselves

    80% confidence

  • Partnering with Scene+, Scotiabank and Tangerine is a major step forward for Shell's loyalty and partner programs, creating the best experience for customers to save and earn rewards when they visit Shell

    80% confidence

  • Shell is an ideal partner for the Scene+ ecosystem as a leader in the fuel industry

    80% confidence

  • Scene+ members told the program they wanted a fuel loyalty partner

    80% confidence

  • Shell joining Scene+ marks a significant milestone for Scotiabank and Scene+ in delivering greater relevance, more value, and a seamless loyalty experience for Canadians

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com